Immunome IMNM
NASDAQ IMNM
$18.00 +0.08 (+0.45%)
At close: Oct 21, 2026 · 4:00 PM EDT

Immunome (IMNM) EBIT Margin (2020 - 2025)

Updated

Immunome's EBIT Margin came in at -3228.83% for FY2025, up 153.54 percentage points from -3382.37% in FY2024.

Analysis

Immunome (IMNM) EBIT Margin (2020 - 2025) Analysis & Trends

  • Per Business Quant, earlier years put EBIT Margin at -3382.37% in FY2024 (-2601.02 pp) and -781.35% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 28.21%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 37.86%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 20.57%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.95%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -133.21%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 28.37%
10 Immunome 2.04 Bn 11.78 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -1,157.61%
Mar 31, 2025 -1,525.50%
Dec 31, 2024 -3,030.31%
Sep 30, 2024 -1,736.15%
Jun 30, 2024 -1,692.43%
Mar 31, 2024 -12,857.05%
Dec 31, 2023 -2,473.94%
Sep 30, 2023 -129.96%
Jun 30, 2023 -135.42%
Mar 31, 2023 -189.13%
Dec 31, 2022 -778,700.00%
Sep 30, 2022 -853,400.00%
Jun 30, 2022 -446,300.00%
Mar 31, 2022 -1,165,400.00%
Jun 30, 2020 -54,300.00%
API Access

Immunome EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=IMNM&period=max&api_key=YOUR_API_KEY